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Abstract
Background: Increase in global health research undertaken in resource poor settings in the last decade though a
positive development has raised ethical concerns relating to potential for exploitation. Some of the suggested
strategies to address these concerns include calls for providing universal standards of care, reasonable availability of
proven interventions and more recently, promoting the overall social value of research especially in clinical
research. Promoting the social value of research has been closely associated with providing fair benefits to various
stakeholders involved in research. The debate over what constitutes fair benefits; whether those that addresses
micro level issues of justice or those focusing on the key determinants of health at the macro level has continued.
This debate has however not benefited from empirical work on what stakeholders consider fair benefits. This study
explores practical experiences of stakeholders involved in global health research in Kenya, over what benefits are
fair within a developing world context.
Methods and results: We conducted in-depth interviews with key informants drawn from within the broader
health research system in Kenya including researchers from the mainstream health research institutions, networks
and universities, teaching hospitals, policy makers, institutional review boards, civil society organisations and
community representative groups.
The range of benefits articulated by stakeholders addresses both micro and macro level concerns for justice by for
instance, seeking to engage with interests of those facilitating research, and the broader systemic issues that make
resource poor settings vulnerable to exploitation. We interpret these views to suggest a need for global health
research to engage with current crises that face people in these settings as well as the broader systemic issues
that produce them.
Conclusion: Global health research should provide benefits that address both the micro and macro level issues of
justice in order to forestall exploitation. Embracing the two is however challenging in terms of how the various
competing interests/needs should be balanced ethically, especially in the absence of structures to guide the process.
This challenge should point to the need for greater dialogue to facilitate value clarification among stakeholders.
Introduction
The last decade has witnessed increased health related
research in resource poor settings mainly in Africa, Asia
and South America [1]. While this increase is a positive
development in addressing neglected diseases [1-4], it also
ushered in new concerns over potential for exploitation
through unfair distribution of risks and benefits among
the parties involved [5-10]. Several strategies to address
these concerns have been promoted in the ethics literature
including calls for universal standards of care [11-13], rea-
sonable availability of proven interventions [14-18] and
more recently, promotion of the overall social value of
research [19]. Closely related to the idea of promoting the
social value of research is the determination of fair benefits
through the consideration of what, if anything, is owed to
those participating in research and their communities, a
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[20-24].
Although there now seems an international consensus
on the need to share benefits arising from global health
research [23,25], there has been continued debate over
what constitutes a fair benefit, whether those that address
the micro level issues of justice (that is those relating to
individual circumstances of those participating in research
[26-28] or those focusing on the macro level (that is, the
broader issues that might predispose participants to
exploitation) [29-32]. The former are often criticised for
ignoring the background conditions of justice [30,33] and
failing to engage fully with communities. Instead, an alter-
native view that proposes better engagement with the
broader social determinants of health (historical grie-
vances, current political, social and economic forces) that
perpetuate poverty and ill health has been proposed
[34,35]. Various counter claims include the charge that
research does not have a primary aim of restoring inequal-
ities or the provision of health care, and should therefore
n o tb es u b j e c tt ot h ep r i n c i p l e so fh e a l t hc a r ep r o v i s i o n
[36]. In addition the approach is seen by some as conflat-
ing benefits in research participation with those of clinical
care [37,38]. Miller for instance [38] has noted that there
is a significant ethical difference between the two, and
conflating the two can lead to errors in ethical judgment.
Despite the intensity of this debate within ethics of glo-
bal health research undertaken in resource poor settings,
previous empiric work on benefits has almost exclusively
focused on micro level issues, and evaluation of alternative
benefits [39-42] and there has been less attention to
empirically examine the practicalities of these positions on
both micro and macro level benefits in real life settings.
We aimed to explore the views of stakeholders involved in
health related research regarding these forms of benefit
sharing in a developing world context.
Context and methods
This work was part of a larger project examining the con-
cept and practice of benefit sharing in health related
research in resource poor settings. Kenya like many other
resource poor settings lacks a well functioning research
governance framework to address ethical issues arising
from increasing volume of international collaborative
health research.
Kenyan health research system
Global health research in Kenya is mainly undertaken
through the national health research system, comprising
of various players coordinated by the Ministry of Higher
Education, Science and Technology (MOHEST) through
the National Council for Science and Technology
(NCST) (See additional file 1). The main players include
the Kenya Medical Research Institute (KEMRI) through
its ten centres, private and public hospitals and universi-
ties, research networks and nongovernmental organisa-
tions both local and international.
Data Collection and analysis
This work is based on 52 in depth interviews conducted
with respondents drawn from institutions involved in glo-
bal health research in Kenya. These institutions were iden-
tified from directorates and discussions with the National
Council for Science and Technology, which is the statutory
body that authorises and grants clearance to undertake
research in Kenya. We therefore aimed to speak to heads
of these institutions and in the case of researchers, the
heads of departments who could provide an overall voice
in terms of the research undertaken. Our recruitment deci-
sions were based on the potential of respondents to give a
rich, deep and thorough account of how the benefits aris-
ing from global health research was decided. Our main
focus therefore was people who could authoritatively speak
on behalf of such institutions that are involved in making
such decisions. Based on this, we focused on interviewing
the leaders of organised groups that are called upon to
facilitate the conduct of health related research. Respon-
dents were drawn from six categories (see table 1) repre-
senting the actors expected to continually engage with
ethical issues arising from the conduct of global health
research. In the case of the community representative
groups, we relied on the already existing community liaison
arrangements under respective research institutions.
Potential respondents were contacted by telephone, to
discuss the study objectives and inclusion criteria. They
were later invited to participate in the study, and arrange-
ments for formal interview made accordingly. Interviews
were conducted face-to-face by the principle investigator
PI, except for a few that were conducted by telephone,
and the final sample was determined by the point of
saturation. All interviews except those with members of
community representative groups were conducted in
English, following an interview guide. Six interview
guides were used corresponding to the category of
respondents as described in table one. The guides were
piloted, revised and those for the community representa-
tive groups translated into Kiswahili. These interview
guides are available on request.
Interview questions focused on interviewee’s familiarity
with the concept of benefit sharing and the description of
the current practice as well as what ought to happen. The
data regarding stakeholder familiarity with the concept of
benefit sharing is however the subject of a separate manu-
script that is under review. The definition of benefit shar-
ing was not immediately provided to the respondents but
discussions over benefits were framed alongside the con-
ceptualisation of benefit sharing provided by Simm Kadri
2005 (ibid) as dealing with concerns over “what, if
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as individuals and groups), and by who, after their partici-
pation, and what, if anything, should be made available to
others in the host community or country during and after
completion of the research”
Interview discussions were audio recorded, transcribed
into MS Word (Microsoft Corporation) and imported into
NVivo 8 software [43] that was used for the indexing,
structuring and theorising during the analysis. Interview
transcripts were read by all investigators to identify mean-
ing units and develop an initial organising system for data
coding. This organising system was developed following a
criterion suggested by Srivastava and Hopwood, [44],
which involved exploring data alongside issues people
were talking about, the original issues that the researcher
set to find out and the contradictions between the two.
Analysis proceeded from open coding, constant compari-
son and coding into each other to the point of saturation
and later organising the codes into themes. We have used
quotes from different stakeholders to illustrate theme and
those themes that are derived from multiple perceptions.
Ethical Considerations
T h es t u d yw a sa p p r o v e db yt h eK e n y aN a t i o n a lE t h i c s
Review Committee (NERC). Informed consent was
obtained from all respondents, including permission to
record the conversation. The interview data presented
here is anonymised by assigning pseudonyms and attribu-
tion only made to the broad category from which the
respondents were recruited to ensure the confidentiality of
respondents.
Results
For simplicity we present stakeholder’s views regarding the
benefits of global health research in three categories
namely, benefits to those taking part in research including
researchers and participating local institutions, benefits to
the wider community in which research is located and
lastly the societal benefits that are associated with success-
ful completion of research.
Benefits to those taking part in research
The first category includes benefits mainly accruing to
participants, researchers and the host institutions.
(i) Access to investigational products and care
“... I think there are several things that come at an
individual level/.../during the time they are in the
study you follow them up, you provide them with free
medical care for the period they are in the study this
one I would say it is a benefit... taking care of their
medical care in our setting is something that most of
us cannot afford especially in our rural areas”
(Researcher 5).
Access to interventions that were being developed
through research was generally regarded as an ideal
form of benefit that should be provided to individuals
directly participating in research. While the above
response is mainly biased towards clinical research, it
was apparent this view was held even where research
involved non medical interventions like training.
Besides access to research interventions participants
also expect to benefit from access to free or improved
medical care more generally, especially through follow-
up by clinicians. These were seen by some as key bene-
fits for several reasons. First, the fact that most people
participating in research cannot afford routine care, and
second that care within a research context is of superior
quality compared to the prevailing standard of care as
illustrated by the quote from a respondent drawn from
a public private partnership.
“... I think compared to normal treatment standards,
patients have a better opportunity...they will see a
Doctor more often, they will be followed up closer
than if they come with Malaria to their local hospi-
tal and get the standard treatment”. (Public private
partnership2).
(ii) Compensation for time and effort
“... But you see, it is almost impossible to call some-
body to walk from some place to come to the other
place and you don’t like give them something. So
incentive is really something in African study or cul-
ture ... “(Researcher 1).
Compensation for time and effort for those participat-
ing in research was identified by several respondents,
Table 1 Institutions from which respondents were recruited
Participating institutions No. of Interviews
Research institutes & University depts. with health science departments/schools/institutes 16
NGOs with research functions 3
Policy makers 4
Ethical review bodies & Research coordinating bodies 11
Pharmaceutical Firms & Other funding bodies 7
Civil Society Organisations (CSOs) & community representative/Advisory groups 11
Lairumbi et al. Philosophy, Ethics, and Humanities in Medicine 2012, 7:7
http://www.peh-med.com/content/7/1/7
Page 3 of 8representing a cross section of stakeholders, as a form of
benefit that should be made available. A related concern
was the demand for reimbursement of direct costs
incurred while participating in research. Those support-
ing compensation as a form of a benefit argued that
incentives and rewards were critical for motivating
participation
Other forms of benefit sharing among those partici-
pating in research were mainly seen as advantageous to
local researchers and institutions.
(iii) Technology transfer
“... we cry for transfer of technology and as a way of
addressing some of these, and that is what we normally
insist on, to try to get some of our people as a Commit-
tee, before we approve a protocol, to be trained in these
things...we try to look at it and say what is there in it
for Kenya in terms of transfer of technology as a benefit
for the country...” (IRB member 4)
Some IRB members attached great significance to
technology transfer because it was seen to be of great
importance to the host country. Different examples of
technology transfer including training and mentorship
of local researchers by collaborating partners from the
north were given as examples. Actual technologies were
also mentioned including laboratory equipment and
techniques for various types of research.
“...when you are mentored by somebody who knows
h o wt od ot h o s ep a r t i c u l a rt h i n g sa f t e rs o m e t i m e s
you will be able to write your own proposal and also
because for example you are writing this with/.../and
he is respected, then they/.../might actually also
respect it (the name of a local mentee)” (Researcher
4).
Opportunities for mentorship were deemed important
in areas like publishing, definition of relevant research
questions and the preparation of high quality research
proposals capable of competing internationally for fund-
ing as illustrated by the following quote by a member of
an IRB;
“ ... They are starving for funds; they are starving for
publications, they starving for name, and so they col-
laborate, come, and we’ll do it” (IRB5).
(iv) Brain gain and retention of qualified personnel
“... he likes to talk about ‘brain gain’ as opposed to
‘brain drain’. I mean the fact is, we are being able to
provide interesting research work for lots of scien-
tists.... but there are a lot of Doctors that are able to
do what they want to do which is to stay in their
o w nc o u n t r ya n dw o r ki nt h e i ro w nc o u n t r y ” (Public
private partnership1).
Several respondents also noted that global health
research provides employment opportunities for local
scientists. The quote by public private partnership 1
uses the metaphor of brain gain to illustrate how global
health research contributes to retention of qualified peo-
ple who might otherwise be lost to developed countries
in the absence of local opportunities. The value of
retaining qualified personnel locally was articulated in
terms of their contribution to the local health care
systems.
(v) Infrastructural development
“... Some of the equipments here are extremely old
and some of the ones that have been bought recently
are mainly because of the projects, otherwise the cen-
tre would have collapsed by now” (Researcher 2)
Besides the support given to individual researchers,
other forms of capacity building might include develop-
ment of the research infrastructure through for instance
the provision of equipment to institutions hosting
research as illustrated in the above quote (and an idea
also linked to the idea of technology transfer).
Respondents gave other examples of capacity strength-
ening especially for institutions like hospitals which host
global health research studies including; (i) expansion of
bed capacity, (ii) provision of ambulances, (iii) ICT con-
nectivity and (iv) training of local healthcare workers in
basic skills to improve the quality of care. Overall such
forms of benefits are regarded as instrumental to
improvements in the quality of healthcare services
offered in those institutions.
The forms of benefits that are articulated in sections i-
iv above mainly aim to benefit research participants,
researchers and the host institutions. The emphasis on
forms of benefits aimed at local researchers and the
local research institutions are clearly evident and the
reason given for this was that, strengthening the capa-
city of the two (local researchers and the research insti-
tutions) is a necessary condition for benefiting the host
countries.
Benefits to the wider community
The second broad category of forms of benefit sharing
within global health mainly targets the wider community
in which research is undertaken. Although research par-
ticipants, researchers and strengthening of local institu-
tions are a part of the community, this category outlines
indirect benefits whose enjoyment is not based on direct
involvement in research but rather are in keeping with
the demands of social justice.
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. “...we want to ensure that if you are carrying
research within a particular community, you need to
give them something back for instance a hospital or
something, even if you are doing clinical research. It
can be anything else that can benefit the community.
Some sort of infrastructure, so that they can at least
see that they are benefiting. Once you have done
that, actually they will feel that they are part of the
process...” (Civil Society Organisation 1).
Some respondents also suggested that provision of
social amenities be considered a form of benefit to the
community. The metaphor of giving back was used var-
iously while appealing to the need to consider the
broader interests of the host community while making
decisions over which benefits to provide.
The rationale for providing such amenities as a valu-
able public good is illustrated by the following quote by
a respondent from a civil society organisation
“... these people can at least feel that actually even
though we are not part of this research, (meaning not
directly participating in the research) our lives have
also improved to some extent, even though I did not
get money as an individual, I can see a nice school
somewhere, I can see a dispensary, I can see a water
point, things like that“. (Civil Society Organisation 3)
(vii) Community mobilisation
“...So the benefits here, let’ss a y ,i st h a tt h ew o m e n
or the community no longer think of going to the
traditional medicine men. They now know that “if
my child has epilepsy, I will go to KEMRI...” (KEMRI
Community Representative 3).
Global health research is also expected to mobilise
communities towards positive changes in health seeking
behaviour. Several community representatives’ groups
noted during the interviews that communities often
acquire better knowledge of disease conditions being
researched when they take part in research, and this
contributes to positive changes in attitudes and practices
towards health promotion.
T h ef o l l o w i n gq u o t eb yam e m b e ro fac o m m u n i t y
representative group further illustrates a case of positive
mobilisation;
“...I think the biggest benefit I have seen is the reduc-
tion in malaria cases, because this disease to be hon-
est had killed many people. The cases reduced, and
all was because those researchers taught us how to
use the nets.../.../some members of the community did
not even know what causes malaria...” (KEMRI Com-
munity Representative 2).
(ix) Other non research related assistance
“... So there is a programme already in place that
benefits them, pays for their school fees, takes them to
school, ploughs their land and plants, give them ferti-
lizer. So you see this entire OVC (Orphans and Vul-
nerable Children) package has benefits and all we’re
asking from that particular population is just to see
what the outcomes are“ (Researcher1).
Global health research is also associated with other
benefits that are not directly related to research. The
above quote for instance illustrates how some research-
ers respond to pressing needs with benefits to the wider
community in return for participation of specific groups
in research. Interestingly, these forms of benefit sharing
were not directly related to the research but were
defined by the community needs.
Societal benefits
The last category of forms of benefit sharing contains
benefits that are aspirational in nature and therefore
mainly result once research is complete.
(x) Availability of medical and public health tools
“...One of the issue is we get new products. I think
that is a good thing because we get to get new pro-
ducts and we can be able to prevent much more dis-
eases that we have been dealing with...“ (Policy
Maker 3).
Global health research was regarded by some as an
opportunity for developing future medical and public
health tools for resource poor settings. Access to such
medical and public health tools was further considered
beneficial in terms of the potential for research evidence
to inform policy and delivery of health care services,
suggesting some value given to research whose final out-
come is generation of knowledge broadly defined. Such
views acknowledge the potentially trans-generational
aspects of research benefits.
(xi) Access to proven interventions
“...I think what we should be asking ourselves is that
okay, “We have several candidates being put in place if
one of them become successful how do we get access to
this vaccine and I think that should be the bigger ques-
tion that people should be asking...“ (Researcher 5).
Apart from providing the opportunity to develop med-
ical and public health tools, global health research is
also expected to promote access to such interventions.
The above quote explicates this expectation, suggesting
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research is an important benefit.
Discussion
We have presented data illustrating different forms of
benefits that are associated with global health research
undertaken in resource poor settings. The forms of bene-
fits are presented along three broad categories that lar-
gely resonate with issues of justice that have dominated
debates within global research ethics for the last decade.
While the forms of benefits that are listed here do not
substantially depart from what has been proposed in the
theoretical literature [27,28,45,46] ours represent a first
attempt to empirically explore the range of benefits that
stakeholders in resource poor setting might expect when
global health research is undertaken in their setting.
More importantly however, the forms of benefits provide
a lens through which to reflect on the social values that
may be expected to inform the ethical acceptability of
global health research in poor settings.
The range of benefits articulated here represents a
combination of both micro and macro level concerns for
justice by, for instance, seeking to engage with interests
of those facilitating research, and the broader systemic
issues that make resource poor settings vulnerable to
exploitation. The demand for access to products under
investigation is an acknowledgement of the need for
research to engage with current crises that face people in
resource poor settings including lack of access to medical
care. In addition, the demand for compensation is seen
here as addressing commutative justice which perhaps
recognises the contribution made by those facilitating
research [47].
In most cases, some forms of benefits that are men-
tioned here have been contentious. For instance, com-
pensation as a form of benefit has been a subject of
longstanding theoretical debate within global research
ethics. Demands for compensation have been debated
broadly as: i) appreciation, ii) compensation and iii)
incentive payments [48]. A key concern is whether com-
pensation induces people into participation [48,49] or
whether it even amounts to coercion [50,51]. Some
bioethicists have also claim e dt h a tc o m p e n s a t i o np a y -
ments might compromise scientific integrity of research
since participants may withhold information that threa-
tens their participation [50,52], while others worry that it
will kill altruism and make research participation a com-
modity to be traded [53]. The potential of payment to be
coercive has however been refuted by others, who see the
claim as false and incoherent [54]. Several models have
also been developed to address the potential for induce-
ment, including the wage payment model [49,55], the
market model [56] and the reimbursement model [57].
What is clear from our work is that participants do have
expectations and that further empiric work could inform
how to select the most appropriate forms of
compensation.
On the other hand, the provision of collateral benefits
such as improving health care, provision of social ame-
nities or community mobilisation have also been criti-
cised as a case of holding global health research to a
different ethic only applicable to health care provision
[58] and one that essentially seeks to correct global
inequality [59].
Conclusion
Contrary to the categorisation of research benefits into
those addressing micro or the macro level issues of jus-
tice, our empiric findings suggest that both are relevant.
Our findings clearly suggest that global health research
is expected to engage with the material conditions that
define settings in which the research is undertaken.
Convincing cases for all the forms of benefits and the
diverse nature of intended beneficiaries can be made.
Embracing all these forms of benefits however presents
ac h a l l e n g eo v e rj u s th o wt h ev a r i o u sc o m p e t i n gi n t e r -
ests/needs can be balanced ethically, especially in the
absence of structures to guide the process. Instead of
providing a definitive solution to this challenge our find-
ings should point to the need for greater dialogue to
facilitate value clarification among stakeholders involved
in global health research. It is clear that work will be
required on a broader question to clarify which forms of
benefits, under which situation could be justified from a
normative perspective.
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